Phaseline

Targets › CCR4

CCR4 (C-C chemokine receptor type 4): drug programs, companies and trials

7 programs from 7 companies in 7 trials: 6 Phase 2, 1 Phase 1; Oncology; next expected readout Nov 2026.

High affinity receptor for the C-C type chemokines CCL17/TARC, CCL22/MDC and CKLF isoform 1/CKLF1. The activity of this receptor is mediated by G(i) proteins which activate a phosphatidylinositol-calcium second messenger system. (UniProt, P51679)

Open in Phaseline: the race on CCR4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Yale UniversityMogamulizumab
C-C chemokine receptor type 4 cross-linking agent
CCR4Phase 2T Cell LymphomaNov 2026
Stanford UniversityMogamulizumab
C-C chemokine receptor type 4 cross-linking agent
CCR4Phase 2Sezary SyndromeDec 2026
University of Michigan Rogel Cancer CenterMogamulizumab
C-C chemokine receptor type 4 cross-linking agent
CCR4Phase 2Cutaneous T Cell LymphomaDec 2026
European Organisation for Research and Treatment of Cancer - EORTCMogamulizumab
C-C chemokine receptor type 4 cross-linking agent
CCR4Phase 2Stage IB-IIB Cutaneous T-Cell LymphomaJan 2027
City of Hope Medical CenterMogamulizumab
C-C chemokine receptor type 4 cross-linking agent
CCR4Phase 2Folliculotropic Mycosis FungoidesJun 2028
Memorial Sloan Kettering Cancer CenterMogamulizumab
C-C chemokine receptor type 4 cross-linking agent
CCR4Phase 2T-Cell Leukemia/Lymphoma, AdultNov 2029
John ReneauMogamulizumab
C-C chemokine receptor type 4 cross-linking agent
CCR4Phase 1Recurrent Adult T-Cell Leukemia/LymphomaJan 2027

Conditions

Sezary Syndrome (1) Recurrent Adult T-Cell Leukemia/Lymphoma (1) Cutaneous T Cell Lymphoma (1) Folliculotropic Mycosis Fungoides (1) T Cell Lymphoma (1) T-Cell Leukemia/Lymphoma, Adult (1) Stage IB-IIB Cutaneous T-Cell Lymphoma (1)

Modalities

antibody (5), mixed (2)

Companies

Stanford University (1) John Reneau (1) University of Michigan Rogel Cancer Center (1) City of Hope Medical Center (1) Yale University (1) Memorial Sloan Kettering Cancer Center (1) European Organisation for Research and Treatment of Cancer - EORTC (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.